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Two receptors with high affinity for salmon calcitonm were cloned from the nucleus accumbens region of rat brain. The deduced 479 amino acid 
sequence of cDNA clone L2175-D20 (designated Cla receptor) is 78% and 66% identical with those reported for human and porcme calcitonin 
receptors, respectively. Clone U3237-A2 codes for a receptor (designated Cl b) that is identical to Cla except for a 37 amino acid insert in the second 
extracellular domain. COS-7 cells transfected with either transcript bound [1251]salmon calcitonin with high affinity (& = 8 pM for Cla; & = 48 
pM for Clb) and responded to salmon calcitonm with increases in CAMP. Tissue distribution studies revealed Cla transcript in rat brain, skeletal 
muscle, kidney and lung, whereas Clb was predominantly found in brain. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Calcitonin receptor cDNAs have recently been 
cloned from porcine LLC-PK, cells [l] and human BIN- 
67 cells [2]. They are members of an emerging subfamily 
of G protein-coupled receptors (GPCRs) that include 
receptors for secretin [3], parathyroid hormone/para- 
thyroid hormone-related peptide (PTH/PTHrP) [4,5], 
glucagon [6], glucagon-like peptide 1 [7], vasoactive in- 
testinal peptide [8] and growth hormone releasing 
hormone [9]. The members of this receptor subfamily 
share 26-51% identity with each other but 5 12% [l] 
with other GPCRs at the amino acid level. 
Binding sites with high affinity for salmon calcitonin 
are concentrated in certain brain regions including hy- 
pothalamus, brainstem, striatum. nucleus accumbens 
and thalamus [lo]. In this report, we describe two 
closely related receptors cloned from rat nucleus accum- 
bens. The receptors were expressed in COS-7 cells for 
measurement of hormone binding and CAMP produc- 
tion. Tissue distribution was evaluated by both North- 
ern blot and PCR methods. Salmon calcitonin-specific 
binding sites in brain have been termed Cl sites [l l] and 
we refer to the two receptors described in this report as 
Cla and Clb receptors. 
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2.1. cDNA librury screening 
An oligo(dT)-primed rat nucleus accumbens cDNA library was 
cloned in eukaryotic expression vector pcDNA1 (Invitrogen; San 
Diego, CA) and transformed into E. coli MCl06l/P3. Plasmid DNA 
was prepared from 72 sublibrary pools of -5000 clones each and sub- 
jected to PCR amplification [12] utilizing a pair of degenerate ohgonu- 
cleottdes corresponding to conserved transmembrane (TM) regions of 
the porcine calcitonm, opossum PTH/PTHrP and rat secretin recep- 
tors. A312 is a mixture of sixteen 18-mers corresponding to the TM3 
sense strand: S-GA(AIG)GG(G/C)(G/C)TCTA(C/T)CTTCAC-3’. 
A313 is a mixture of sixty-four 17-mers corresponding to the TM7 
antisense strand: 5’-(T/C)(C/G)(A/G)TTG(C/A)(A/G)GAA(G/A) 
CAGTA-3’. Products were Southern blotted and probed [13] with a 
third degenerate oligonucleotide (A315) corresponding to a different 
TM7 region of the calcitonin and PTH/PTHrP receptors: 5’- 
GCAACGAA(G/A)AATCCCTGGAA-3’. Two positive pools were 
subdivided and rescreened until single bacterial transformants were 
isolated. 
2.2. 5’ RACE 
Amplification and isolation of the upstream 5’ ends of the receptor 
cDNAs was accomplished using the technique of rapid amplification 
of cDNA ends [14,15] (5’ RACE system; Grbco BRL. Gaithersburg, 
MD) following the manufacturer’s protocol. Briefly, 100 ng rat nu- 
cleus accumbens poly(A)+ RNA was converted to first strand cDNA 
using A333 gene-specific primer (TM7: antisense strand): 5’- 
CCCTGGAAATGAATCAGAGAG-3’. Subsequent PCR amplifica- 
tion employed gene-specific primer A361 (E4 domam; antisense 
strand): 5’-(CAU),ATAATCATAGATCTTCCCAAGC-3’. 
Specific amplification products were identified by Southern blotting 
and probing with a 656 bp TM2-7 probe from clone pcDNAI-237. 
They were subsequently subcloned and partially sequenced. 
2.3. Construction of full-length receptor cDNAs 
Corresponding S’RACE and cDNA library clone fragments were 
ligated into PstILXbaI linearized eukaryotic expression plasmid 
pcDNA1 and introduced into E. coli MCl06l/P3. For the Cla recep- 
tor, pAMPl-L2 provides the -1.2 kb sequence from a unique PstI site 
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m the S-untranslated region (-60 bp downstream of the Y-end of the 
PCR amplified fragment) to a unique StrrI site m the I3 domam. 
pcDNAI-175 provides the corresponding -2.2 kb sequence from the 
same SfzrI site through the poly(A) tat1 at the 3’-end of the cDNA 
followed by an XhaI site introduced by the clomng. Similarly for the 
Clb receptor, S’RACE clone pAMPI-U3 provides the -1.3 kb P.\tI- 
Stul fragment ligated to its correspondmg -2 2 kb Srrtl SpeI fragment 
from cDNA library clone pcDNAI-237. 
2.4. DNA sequrnca,g 
DNA was sequenced by the dideoxy cham-termination method [ 161 
usmg a combination of nested deletions and synthetic ohgonucleotide 
primers with modified phage T7 DNA polymerase (Sequenase; Umted 
States Btochemicals. Cleveland. OH). 
A Northern blot containmg 2 pg of poly(A)’ RNA from eight rat 
tissues (Clonetech. Palo Alto. CA) was probed [13] with a 1244 bp 
HlndIII-EurI coding region fragment from clone L2175D20. The blot 
was washed m 2 x SSCIO.l% SDS at 50°C and exposed to XAR film 
at -80°C with intensifying screens. 
RT-PCR usmg 50 ng of poly(A)’ RNA from a variety of rat tissues 
was accomplished using reagents from the GeneAmp RNA PCR kit 
(Perkin-Elmer-Cetus; Norwalk. CT) followmg the manufacturers m- 
structions. First strand cDNA was amplified using upstream primer 
A356 (TMZ; sense strand) 5’-GTTGAGGTTGTGCCCAATGGA-3’ 
and downstream primer A333 for 30 cycles. Products were Southern 
blotted and probed with a 656 bp TM?- 7 probe from clone pcDNAI- 
237. The blot was washed in 0.2 x SSC/O I % SDS at 6YC and exposed 
to film. 
2.6. Transreni trunsjhon 
Monolayers of COS-7 cells m T-150 tissue culture flasks were trans- 
fected with 14pg plasmid DNA and 12Oflg Lipofectm reagent (Gibco 
BRL) m 10 ml Optimem media (Gibco BRL) containing 5.5 PM 
2-mercaptoethanol Cells were incubated at 37°C m a 5% CO, atmos- 
phere for 4 h after which the transfection medium was replaced with 
DMEM (low glucose, 1000 mg/l)/lO% fetal bovine serum/2% L-glu- 
tamine/l% pemcilhn-streptomycin. 60 h post-transfection, cell homo- 
genates were prepared m ice-cold 20 mM HEPES, ahquoted and 
stored at -80°C. 
Membranes from transfected COS cells were incubated (in quadru- 
plicate) for 1 h at 23°C with [“LI]iodotyrosyl-salmon calcitonin (2.000 
Ci/mmol: Amersham, Arhngton Heights. IL) in a buffer composed of 
20 mM HEPES. pH 7.4/l mgm-’ BSAll mgm-’ bacitracin/l pgm-’ 
phosphoramidon/5 pgm-’ bestatin-HCI and were collected on glass 
fiber filters pretreated with 0.3% polyethyleneimine. Filters were 
washed with ice cold PBS. dried and assayed for radioactivity. Mem- 
brane concentrations were chosen in which specific binding was linear 
with protein concentration (1.3 pgm-’ for Cla; 13 @gm-’ for Cl b). 
Binding of [“51]salmon calcttomn was measured at concentrations 
varying from I-150 pM to obtain total binding, and again m the 
presence of 100 nM unlabeled salmon calcitonin to obtain nonspecific 
binding. Competition curves were generated by measurmg the binding 
of 8 pM or 20 pM [“‘I]salmon calcitonin to Cla-expressing and Cl b- 
expressing membranes, respectively. in the presence of lo-” to 1O-6 M 
competing peptide Apparent inhibition constants (k;s) were derived 
from IC5,, values using the Cheng-Prusoff equation (Inplot 4 03, 
GraphPAD, San Diego, CA). Proteins were measured accordmg to 
the method of Bradford with BSA as control. Unlabeled peptides were 
from Bachem (Torrance, CA). 
24 h dfter transfection cells were subcultured at 1 x 10’ cells/O 2 ml 
medium/well m 96-well tissue culture plates After an additional 24 h. 
cells were preincubated for 20 min with 100/l Dulbecco’s phosphate- 
buffered salute, pH 7.3 (DPBS. Sigma) containing 0.1 mgm-’ BSA 
and 0.05 mgm-’ isobutylmethyl xanthme, followed by 25 min incuba- 
tion with added hormone The response was halted by acidification 
wtth 25 ~1 10% trichloroacetic actd followed by neutralization with 25 
~1 0.8 M Tris (hydroxymethyl) aminomethane Immunoreactive 
CAMP m supernatants was quantitated after acetylation using a scin- 
ttllation proximity assay (Amersham. Arlington Heights, IL). 
3. RESULTS AND DISCUSSION 
3.1. A4olecular clorziig 
We identified two distinct calcitonin receptor 
isoforms using mixtures of oligonucleotides corre- 
sponding to conserved regions in TM3 and TM7 of the 
calcitonin. PTH/PTHrP and secretin receptors as prim- 
ers to amplify and clone potentially homologous se- 
quences from a rat nucleus accumbens cDNA library. 
Partial DNA sequencing of two clones, pcDNAI-175 
and pcDNAI-237, revealed that both were similar to the 
porcine calcitonin receptor [l] but that neither was full- 
length. The two cDNAs were identical over the region 
sequenced (TM2-7) except for a 111 bp insert in the E2 
domain of pcDNAI-237. We employed 5’ RACE to 
amplify the unknown sequence at the 5’-ends of the 
receptor transcripts. One product (pAMPI-L2) was 
identical to pcDNAI-175 from TM2 through E4 while 
a second product (pAMPl-U3) was identical to 
pcDNAI-237 over the same region, including the 1 I1 bp 
insert in E2. Full-length sequences for each of the two 
receptors suitable for expression were constructed by 
ligating corresponding S’RACE and cDNA library se- 
quences into the eukaryotic expression vector pcDNAI. 
The nucleotide sequences of both clones and their 
deduced Cl a and Cl b receptor sequences are presented 
in Fig. 1. The receptors differ only by a 37 amino acid 
segment present in the E2 domain of Cl b. Except for 
the 111 bp insert encoding this segment. there are only 
two nucleotide differences (both of which are silent at 
the amino acid level) suggesting these receptors may be 
alternatively spliced transcripts of a single message. 
Two dopamine D, receptor isoforms that differ by a 29 
amino acid insert in the I3 domain occur in human [I 91, 
Fig. 1. Nucleottde and deduced amino acid sequences of rat clone L2175-D20 coding for the Cl a receptor. The numbering of the nucleotides and 
the amino acids ts shown at the right and left of each line. respectively. The seven predicted membrane-spanning domains [17] are underlined. Four 
potential extracellular N-linked carbohydrate attachment sites are double underlined. The predicted stgnal sequence cleavage site [18] is indicated 
by a filled triangle (A). Clone U3237-A2 codmg for the Clb receptor was sequenced from nucleotide positions l-1697 and is identical except for 
a T at position 1093. a C at position 1186. and the following 111 bp insert between positions 891 and 892: GCATATTTTTCATCATAACAC- 
ATATATGTGGACAATGCAGTGGGAACTGTCACCACCCTTACCCCTGAGTGCACACGAGGGAAAGATGGACCCTCATGACAGT- 
GAAGTGAT. This insert codes for an additional 37 residues between ammo acid positions 216 and 217: MHIFHHNTYMWTMQWELSPPLPL- 
SAHEGKMDPHDSEV. 
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Fig 2. Alignment of the rat Cla and Clb receptors with the human [2] and porcme [l] calcitonin receptors. Ammo acid Identities are shown by 
a vertical hne (I) and conservative amino acid replacements by a colon (‘). Gaps have been mtroduced to maximize the alignment. The seven potential 
transmembrane (TMIL7) domams [17] are mdrcated by hortzontal lines. Extracellular (E1-3) and mtracellular (11-4) domams are marked The 
228 
numbermg of the ammo acids for the receptors is shown in the right margm. 
Volume 325. number 3 FEBS LETTERS 
2.4- 
1.35- 656bp --, 
545bp + 
__ 
Fig. 3. Tissue distribution of transcripts for Cla and Clb receptors. (A) Northern blot of poly (A)’ RNA from rat tissues hybridized with a receptor 
coding region probe. RNA size markers (kb) are indicated to the left. The Integrity of the RNA samples on this Northern blot was subsequently 
verified by hybridization with a/?-actin probe (data not shown). Abbreviations: HRT, heart; BRN, brain; SPL, spleen: LUN. lung; LIV, liver; SKM, 
skeletal muscle; KID, ktdney; TES, testis. (B) Southern blot of RT-PCR products from a variety of rat tissue poly(A)’ RNA hybridized with a 
receptor coding regton probe. The mtegrtty of the poly(A)’ RNA samples used in these RT-PCR amplifications and successful conversion to cDNA 
was demonstrated by the PCR amplification of a 983-bp fragment of rat glyceraldehyde- 3-phosphate dehydrogenase cDNA from the same sample 
used for the above amplification (data not shown). Abbreviations: CE. cerebellum. NA, nucleus accumbens, SOL, soleus muscle; GAS, gastrocne- 
mius muscle; SKM. skeletal muscle; SMM. smooth muscle; LIV, liver: LUN, lung; OV, ovary; PAN, pancreas; KID, kidney: dH?O, water negative 
control. 
bovine [20], and rat [20,21] brain. The calcitonin recep- 
tors described herein appear to be another system in 
which diversity is achieved by alternative splicing. 
An in-frame termination codon at position 173 is 
followed by three potential in-frame AUG translation 
initiation codons at positions 19 1, 2 12, and 242 (Fig. 1). 
All three include an A at the +4 position and an A at 
the -3 position that is sufficient for translation initia- 
tion [22]. However, translation from either upstream 
site results in a protein beginning with 10 or 17 amino 
acids with a rather hydrophilic nature not typical of a 
signal sequence. Therefore, the putative translation ini- 
tiation site was assigned at position 242 based on its 
similarity to porcine and human calcitonin receptor ini- 
tiation sites and its hydrophobic profile resembling a 
more prototypical leader sequence. 
The rat Cla and Clb receptors display the cardinal 
features of the secretin-type peptide receptor family, 
including a large El domain with 14 conserved cysteine 
residues and several conserved potential N-linked gly- 
cosylation sites (Asn-X-Ser/Thr), as well as the seven 
transmembrane domain topography [23] shared by all 
G protein-coupled receptors. The rat Cla receptor 
shares 66% overall sequence identity to the calcitonin 
receptor cloned from the porcine renal LLC-PK, cell 
line [l] and 78% sequence identity to a human calcitonin 
receptor cloned from the BIN-67 cell ovarian carcinoma 
[2] (Fig. 2). They also share a site in the 14 domain 
(R-R-P-T4’3) for potential phosphorylation by CAMP- 
dependent protein kinase [24]. 
3.2. Tissue distribution 
Northern blot analysis was performed using RNA 
from various tissue sources and probing with a nearly 
complete coding region sequence of the Cl a receptor. 
A single band of -4.4 kb was identified in rat brain and 
kidney but could not be detected under the conditions 
employed in heart, spleen, lung, liver, skeletal muscle, 
or testis (Fig. 3A). Identical results were obtained using 
a TM 2-7 probe from the Clb receptor sequence (data 
not shown). 
The tissue-specific distribution of these transcripts 
was further investigated by qualitative RT-PCR on a 
variety of rat tissue RNA. Distribution of each of the 
two receptors was distinguished using primers flanking 
the 111 bp insert present in the Cl b receptor but not in 
229 
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Fig. 4. Bindmg isotherms for [“SIliodotyrosyl-salmon calcitonin with COS-7 cell membranes transiently expressing rat Cla receptor (A) or rat CI b 
receptor (B) Inset. Scatchard plot of the specific bmdmg. 
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the Cla receptor. The predicted 545 bp product corre- 
sponding to the Cla receptor was again demonstrated 
in brain and kidney, and additionally in skeletal muscle 
and lung (Fig. 3B). In contrast, the predicted 656 bp 
product corresponding to the Clb receptor was present 
predominantly in brain, although it could be detected 
in muscle, lung, and kidney upon longer exposure of the 
blot. Neither transcript was detected in liver, ovary or 
pancreas. Sequencing the amplified fragment from rat 
gastrocnemius muscle indicated that it was identical to 
the Cla sequence over the 470 bp region between TM2 
and TM7, although the possibility of differences outside 
this region cannot be eliminated. A third product with 
mobility between the 656 bp and 545 bp fragments is 
also evident in amplification from nucleus accumbens 
RNA. We believe it is a heteroduplex of the Cla and 
Cl b products: (i) multiple subclones of this gel isolated 
fragment were either the 656 bp or 545 bp product; and 
(ii) it could be formed by subjecting a mixture of the 656 
bp and 545 bp products to thermal cycling in the ab- 
sence of DNA polymerase. 
3.3. Receptor expression and binding studies 
Full-length receptor cDNA constructs were ex- 
pressed by transient transfection of COS-7 cells in order 
to determine the ligand binding properties of these 
unique receptors. Specific and saturable binding of 
[“‘Iliodotyrosyl-salmon calcitonin was observed in 
membranes from COS cells expressing either Cla (Fig. 
4A) or Clb receptors (Fig. 4B). Membranes from COS 
cells transfected with the pcDNA1 vector without any 
cDNA insert did not exhibit specific binding of 
[“51]salmon calcitonin. Scatchard analysis of C 1 a satu- 
ration data yielded a dissociation constant (K,) of 
8.2 + 0.3 pM and a binding site density (B,,,) of 
3.9 IL 1.3 pmol/mg protein (mean ? S.D., 2 experi- 
ments). Scatchard analysis of Clb saturation data 
yielded a Kd of 47.8 !I 2.8 pM and a B,,, of 0.92 ?I 0.03 
pmol/mg protein. Salmon calcitonin potently competed 
for [‘251]salmon calcitonin binding to both Cla 
(K, = 14 + 2 pM, n = 3) and Clb (K,=113+6 pM, n=3) 
receptor-expressing cell membranes. K,s for unlabeled 
salmon calcitonin measured in competition experiments 
were somewhat lower affinity than the Kds for radio- 
iodinated salmon calcitonin measured by saturation 
binding, but again demonstrated the significant 6- to 
&fold difference in affinity between C la and C 1 b recep- 
tors. Rat calcitonin was weak at inhibiting [“‘I]salmon 
calcitonin binding to either receptor (IC,, > 1 ,uM). 
3.4. Stimulation of CAMP production 
As with other members of the secretin-type receptor 
family, the Cla and Cl b receptors stimulate adenylate 
cyclase activity upon expression in COS cells (Fig. 5) 
and contain a motif in the 13 domain (R-X1,-K-A-V- 
K343) postulated to be involved in coupling to Gs, [25]. 
Control COS-7 cells transfected with the pcDNA1 ex- 
2.0 
= 
z! 
g 1.5 
Q 
0 
0.0 
Cla Clb Vector control 
Receptor 
Fig. 5 Cychc AMP production in COS cells transiently transfected 
with the Cla or Clb receptor. Cells were incubated with buffer alone 
(filled bars), 1 PM salmon calcitonin (shaded bars), or 10 ,uM iso- 
proterenol (cross-hatched bars). Values are means f S.D. (n = 8). 
pression vector alone were unresponsive to salmon cal- 
citonin. All cells showed equivalent CAMP production 
in response to isoproterenol which activates the adenyl- 
ate cyclase-linked p adrenergic receptor. Salmon calci- 
tonin stimulated adenylate cyclase activity in mem- 
branes from rat kidney but not in membranes from rat 
spinal cord [26] or hypothalamus [27]. Cla and Clb 
receptors were capable of stimulating adenylate cyclase 
activity when expressed in COS-7 cells. Perhaps these 
receptors are uncoupled from adenylate cyclase during 
isolation of brain membranes. or they may couple to a 
different transduction system in brain cells. 
3.5. Summary 
We have identified and cloned two receptor isoforms 
from rat nucleus accumbens that bind salmon calcitonin 
with high affinity and can couple to stimulation of 
adenylate cyclase activity. It has come to our attention 
that two similar calcitonin receptor isoforms have re- 
cently been cloned from a rat hypothalamus cDNA 
library (P. Sexton, personal communication). The role 
of Cla and Clb receptors in central nervous system 
function is not known. Intracerebral injection of salmon 
calcitonin produces analgesia [28], anorexia [29], inhibi- 
tion of gastric acid secretion [30], inhibition of amphet- 
amine-induced locomotor activity [31] and inhibition of 
prolactin secretion [32], demonstrating that salmon cal- 
citonin activates functional central receptors. While 
salmon calcitonin is not present in mammals, sub- 
stances that display salmon calcitonin-like im- 
munoreactivity have been reported in brain and thyroid 
[33], lung cancer [34] and prostate [35]. Salmon calci- 
tonin immunoreactive material isolated from rat hypo- 
thalamus is reported to be functionally active [36]. 
These reports point to the existence in the rat of salmon 
calcitonin-related peptides, one or more of which could 
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be active at the Cla and/or Cl b receptors. The presence 
of C 1 a transcript, and presumably C 1 a receptor, in skel- 
etal muscle may account for the recent findings that 
salmon calcitonin potently reduces incorporation of 
glucose into glycogen (K. Beaumont and A. Young, 
unpublished) and stimulates sodium pump activity [37] 
in rat soleus muscle, both actions likely mediated by 
increased CAMP. 
The two receptors cloned from nucleus accumbens 
differ by a 37 amino acid insert in the predicted E2 
domain that is associated with significantly lower bind- 
ing affinity for salmon calcitonin. This is the first exam- 
ple we are aware of where an amino acid insert in a G 
protein-coupled receptor has been found to alter ligand 
binding and it may provide a novel mechanism for the 
modulation of receptor responsiveness. These results 
also provide structural evidence for intraspecies calci- 
tonin receptor heterogeneity and, together with existing 
pharmacological data [3840], indicate that actions of 
calcitonins may be mediated by distinct receptor sub- 
types. Studies with receptor-specific pharmacological 
agents will help in determining the functional signifi- 
cance of the calcitonin receptor isoforms identified in 
these tissues. 
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